Maze Therapeutics (NASDAQ:MAZE) Stock Price Expected to Rise, Wedbush Analyst Says

Maze Therapeutics (NASDAQ:MAZE) had its price objective raised by investment analysts at Wedbush from $43.00 to $58.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s price target would suggest a potential upside of 15.51% from the stock’s current price.

Other equities analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating on shares of Maze Therapeutics in a research note on Wednesday, January 28th. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. BTIG Research reiterated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research note on Monday, March 9th. Finally, Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $57.38.

Maze Therapeutics Price Performance

Maze Therapeutics stock opened at $50.21 on Monday. The stock has a market capitalization of $2.42 billion, a P/E ratio of -2.40 and a beta of 4.46. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $52.86. The firm’s 50-day moving average is $44.82 and its two-hundred day moving average is $35.90.

Insiders Place Their Bets

In other Maze Therapeutics news, CMO Harold Bernstein sold 45,000 shares of Maze Therapeutics stock in a transaction on Monday, December 29th. The shares were sold at an average price of $40.56, for a total value of $1,825,200.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Atul Dandekar sold 72,400 shares of the business’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the sale, the insider directly owned 10,503 shares of the company’s stock, valued at $426,001.68. This represents a 87.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 230,000 shares of company stock valued at $9,768,292 over the last quarter.

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its holdings in shares of Maze Therapeutics by 318.0% in the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after purchasing an additional 2,390,713 shares during the period. Vanguard Group Inc. grew its holdings in shares of Maze Therapeutics by 218.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock worth $34,615,000 after purchasing an additional 915,342 shares during the period. Marshall Wace LLP increased its position in Maze Therapeutics by 3,868.5% during the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock worth $20,166,000 after purchasing an additional 758,104 shares in the last quarter. Caligan Partners LP purchased a new position in Maze Therapeutics in the fourth quarter valued at approximately $22,794,000. Finally, ArrowMark Colorado Holdings LLC purchased a new position in Maze Therapeutics in the third quarter valued at approximately $14,135,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.